TherapeuticsMD, Inc. Receives Notice Of Allowance For Patent Covering Platform Technology Of Oral Combination Bioidentical 17ß-Estradiol And Progesterone

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT:TXMD), a women’s healthcare company ("TherapeuticsMD" or the "Company"), announced today that it received a Notice of Allowance from the U.S. Patent and Trademark Office pertaining to its U.S. Patent Application 13/684,002 - "Natural Combination Hormone Replacement Formulations and Therapies." This Patent Application covers the Company’s platform technology TX 12-001-HR, its oral bioidentical 17ß-estradiol and progesterone combination drug candidate.

Help employers find you! Check out all the jobs and post your resume.

Back to news